Regeneron Pharmaceuticals, Inc. $REGN is Persistent Asset Partners Ltd’s 5th Largest Position

Persistent Asset Partners Ltd boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 428.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,911 shares of the biopharmaceutical company’s stock after buying an additional 5,602 shares during the quarter. Regeneron Pharmaceuticals accounts for approximately 2.7% of Persistent Asset Partners Ltd’s portfolio, making the stock its 5th largest holding. Persistent Asset Partners Ltd’s holdings in Regeneron Pharmaceuticals were worth $3,886,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. CoreCap Advisors LLC boosted its position in Regeneron Pharmaceuticals by 9.2% during the third quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 20 shares in the last quarter. Strait & Sound Wealth Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 3.5% during the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock worth $353,000 after buying an additional 21 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in shares of Regeneron Pharmaceuticals by 14.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock worth $92,000 after buying an additional 21 shares in the last quarter. Independence Bank of Kentucky grew its stake in Regeneron Pharmaceuticals by 7.7% in the 3rd quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock valued at $173,000 after acquiring an additional 22 shares during the last quarter. Finally, Redwood Wealth Management Group LLC increased its holdings in Regeneron Pharmaceuticals by 4.8% during the 2nd quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 23 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,636 shares of company stock worth $2,862,920 in the last ninety days. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $782.38 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The business has a 50-day moving average of $768.21 and a two-hundred day moving average of $671.68. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The firm has a market capitalization of $82.71 billion, a PE ratio of 18.83, a P/E/G ratio of 2.13 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the company posted $12.07 earnings per share. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be issued a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.47%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Wells Fargo & Company increased their target price on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price target for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Oppenheimer reaffirmed an “outperform” rating and set a $865.00 price objective (up previously from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Finally, HSBC upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $793.81.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.